NovoCure Ltd (NASDAQ: NVCR) on Friday, plunged -3.76% from the previous trading day, before settling in for the closing price of $31.90. Within the past 52 weeks, NVCR’s price has moved between $11.70 and $34.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 17.16% over the last five years. The company achieved an average annual earnings per share of 32.60%. With a float of $97.35 million, this company’s outstanding shares have now reached $108.10 million.
The firm has a total of 1453 workers. Let’s measure their productivity. In terms of profitability, gross margin is 76.41%, operating margin of -27.51%, and the pretax margin is -19.82%.
NovoCure Ltd (NVCR) Insider Activity
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of NovoCure Ltd is 10.03%, while institutional ownership is 85.90%. The most recent insider transaction that took place on Nov 02 ’24, was worth 734. In this transaction Chief Operating Officer of this company sold 44 shares at a rate of $16.69, taking the stock ownership to the 3,459 shares. Before that another transaction happened on Oct 31 ’24, when Company’s Chief Human Resources Officer sold 810 for $15.79, making the entire transaction worth $12,792. This insider now owns 110,093 shares in total.
NovoCure Ltd (NVCR) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.36 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 32.60% per share during the next fiscal year.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
NovoCure Ltd (NVCR) is currently performing well based on its current performance indicators. A quick ratio of 1.44 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.53.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.39, a number that is poised to hit -0.36 in the next quarter and is forecasted to reach -1.63 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
Analysing the last 5-days average volume posted by the [NovoCure Ltd, NVCR], we can find that recorded value of 0.82 million was lower than the volume posted last year of 1.32 million. As of the previous 9 days, the stock’s Stochastic %D was 32.48%. Additionally, its Average True Range was 1.98.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 82.82%, which indicates a significant increase from 47.79% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.32% in the past 14 days, which was lower than the 93.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.17, while its 200-day Moving Average is $18.58. Now, the first resistance to watch is $31.71. This is followed by the second major resistance level at $32.72. The third major resistance level sits at $33.39. If the price goes on to break the first support level at $30.03, it is likely to go to the next support level at $29.37. Should the price break the second support level, the third support level stands at $28.36.
NovoCure Ltd (NASDAQ: NVCR) Key Stats
Market capitalization of the company is 3.20 billion based on 108,201K outstanding shares. Right now, sales total 509,340 K and income totals -207,040 K. The company made 155,100 K in profit during its latest quarter, and -30,570 K in sales during its previous quarter.
